Select therapeutic use:
Indications for Bumetanide Inj:
Initially 0.5–1mg IM or IV. May give 1–2 more doses at 2–3 hour intervals; max 10mg/day.
<18yrs: not recommended.
Anuria. Infants. Hepatic coma. Severe electrolyte depletion.
Hepatic cirrhosis. Ascites. Progressive renal disease. Gout. Diabetes. Postsympathectomy. Monitor electrolytes, blood, liver function. May need K+ supplementation. K+ losing nephropathy. Discontinue if renal dysfunction progresses. Aldosterone excess. Ventricular arrhythmias. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
May increase digitalis, lithium toxicity. Hypokalemia with digitalis, diuretics in CHF. Alcohol, CNS depressants increase orthostatic hypotension. Avoid probenecid, indomethacin. Ototoxicity may be potentiated with aminoglycosides.
Muscle cramps, dizziness, hypotension, headache, nausea, encephalopathy, ototoxicity, rash, fluid or electrolyte imbalance, hyperglycemia, hyperuricemia, blood dyscrasias.
Formerly known under the brand name Bumex.